The design and synthesis of a novel, orally active, selective ETA antagonist

Medicinal Chemistry Research

Volumn 13, Issue 3-4, 2004, Pages 149-157

  Rawson, David J ^a   Dack, Kevin N ^a   Dickinson, Roger P ^a   James, Kim ^a   Long, Clive ^a,b   Walker, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 546; ATRASENTAN; BOSENTAN; DARUSENTAN; DRUG METABOLITE; ENDOTHELIN A RECEPTOR ANTAGONIST; SITAXSENTAN;

BINDING AFFINITY; CLINICAL TRIAL; COMPUTER MODEL; CONFERENCE PAPER; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATION; STRUCTURE ANALYSIS;

EID: 10644275211     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-004-0021-y     Document Type: Conference Paper

References (20)

1. Yanagisawa, M.; Kurihra, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. Nature (London), 1988, 332, 411.
2. (a) Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Nature (London), 1990, 348, 730;
3. (b) Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Nature (London), 1990, 348, 732;
4. (c) Karne, S.; Jayawickreme, C.K.; Lerner, M.R. J. Biol. Chem., 1993, 268, 19126.
5. Rodeheffer, R.J.; Lerman, A.; Heublein, D.M.; Burnett, J.C.Jr. Am. J. Hypertension, 1991, 4, 9A.
6. Stewart, D.J.; Levy, R.D.; Cernacek, P.; Langleben, D. Ann. Internal Medicine, 1991, 114, 464.
7. Stockenhuber, F.; Gottsauner-Wolf, M.; Marosi, L.; Liebisch, B.; Kurz, R.W.; Balcke, P. Clin. Sci. (London), 1992, 82 (3), 255.
8. Stewart, J.T.; Nisbet, J.A.; Davies, M.J. Br. Heart. J., 1991, 66, 7.
9. For a recent review on Endothelin Antagonists see: Benigni, A.; Remuzzi, G. Lancet, 1999, 353 (9147), 133.
10. Roumen, N.; Egon, P. and Eberle, S., 2002, J. Hypertension, 15 (7, Pt 1), 583-589.
11. Rawson, D.J.; Dack, K.N.; Dickinson, R.P. and James, K. 2002, Biorg. Med. Chem. Lett., 12, 125-128.
12. Initial work was carried out in the racemic series and the data presented on compounds 1-15 is from this series. Compounds 7a and 8a were synthesised and profiled as single enantiomers.
13. For further examples of antagonists sharing these pharmacophoric features see: Bunker, A.M.; Edmunds, J.J.; Berryman, K.A.; Walker, D.M.; Flynn, M.A.; Welch, K.M., Doherty, A.M. Biorg. Med. Chem. Lett., 1996, 6, 1061 and Elliot, J.D.; Lago, M.A.; Cousins, R.D.; Gao, A.; Leber, J.D.; Erhard, K.F.; Nambi, P.; Elshourbagy, N.A.; Kumar, C. J. Med Chem., 1994, 37, 1553.
14. For further examples of antagonists sharing these pharmacophoric features see: Bunker, A.M.; Edmunds, J.J.; Berryman, K.A.; Walker, D.M.; Flynn, M.A.; Welch, K.M., Doherty, A.M. Biorg. Med. Chem. Lett., 1996, 6, 1061 and Elliot, J.D.; Lago, M.A.; Cousins, R.D.; Gao, A.; Leber, J.D.; Erhard, K.F.; Nambi, P.; Elshourbagy, N.A.; Kumar, C. J. Med Chem., 1994, 37, 1553.
15. Lipinski, C.A.; Lombardo, F.; Dominy B.W. and Feeney P.J. Adv Drug Delivery Rev., 1997, 23, 3-25.
16. Yee, S. Pharm Res (NY) 1997, 14, 763-766.
17. Raevsky, O.A. Verlag Helvetica Chimica Acta, Basel, Hydrogen bond strength estimation by means of the HYBOT program package, in Computer-assisted lead finding and optimization (van de Waterbeemd H. Testa B Folkers G eds), 1997, 369-378.
18. Walker, D.K.; Dack, K.N.; Dickinson, R.P.; Fenner, K.S.; James, K.; Rawson, D.J. and Smith, D.A. Drug Met. And Disp. 2001, 29, 1424-1431.
19. Artursson, P.; Palm, K. and Luthman, K. Adv Drug Delivery Rev. 1996, 22:67-84.
20. van de Waterbeemd, H.; Camenisch, G.; Folkers, G and Raevsky, O.A. Quant Struct-Act Relat., 1996, 15,480-490.